3.13
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt IOVA?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$2.49
Offen:
$2.78
24-Stunden-Volumen:
49.01M
Relative Volume:
3.26
Marktkapitalisierung:
$1.05B
Einnahmen:
$32.77M
Nettoeinkommen (Verlust:
$-440.22M
KGV:
-1.8743
EPS:
-1.67
Netto-Cashflow:
$-400.48M
1W Leistung:
+61.34%
1M Leistung:
+58.08%
6M Leistung:
-47.75%
1J Leistung:
-62.42%
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Firmenname
Iovance Biotherapeutics Inc
Sektor
Branche
Telefon
(650) 260-7120
Adresse
825 INDUSTRIAL ROAD, SAN CARLOS
Vergleichen Sie IOVA mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
IOVA
Iovance Biotherapeutics Inc
|
3.13 | 647.83M | 32.77M | -440.22M | -400.48M | -1.67 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-07-15 | Herabstufung | Goldman | Neutral → Sell |
2025-05-16 | Herabstufung | UBS | Buy → Neutral |
2025-05-12 | Herabstufung | Truist | Buy → Hold |
2025-05-09 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
2024-10-24 | Eingeleitet | UBS | Buy |
2024-07-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
2023-11-20 | Eingeleitet | Goldman | Buy |
2023-09-18 | Bestätigt | Barclays | Overweight |
2023-05-30 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
2023-03-27 | Fortgesetzt | Wells Fargo | Equal Weight |
2023-01-27 | Hochstufung | Piper Sandler | Neutral → Overweight |
2022-12-09 | Herabstufung | Goldman | Buy → Neutral |
2022-10-31 | Eingeleitet | Guggenheim | Neutral |
2022-08-18 | Fortgesetzt | Wells Fargo | Equal Weight |
2022-01-28 | Hochstufung | Stifel | Hold → Buy |
2021-12-07 | Fortgesetzt | Cowen | Outperform |
2021-06-10 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
2021-05-20 | Herabstufung | Piper Sandler | Overweight → Neutral |
2021-05-19 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
2021-05-19 | Herabstufung | Stifel | Buy → Hold |
2021-05-03 | Eingeleitet | Truist | Buy |
2021-04-16 | Eingeleitet | Goldman | Buy |
2021-03-08 | Hochstufung | H.C. Wainwright | Neutral → Buy |
2020-12-15 | Herabstufung | H.C. Wainwright | Buy → Neutral |
2020-10-06 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
2020-04-22 | Eingeleitet | Mizuho | Buy |
2020-03-04 | Eingeleitet | Barclays | Overweight |
2020-02-26 | Bestätigt | H.C. Wainwright | Buy |
2020-02-26 | Bestätigt | Oppenheimer | Outperform |
2019-12-18 | Eingeleitet | JMP Securities | Mkt Outperform |
2019-10-01 | Eingeleitet | Stifel | Buy |
2019-04-29 | Eingeleitet | Piper Jaffray | Overweight |
2019-02-28 | Bestätigt | Chardan Capital Markets | Buy |
2019-02-07 | Eingeleitet | Robert W. Baird | Outperform |
2018-12-31 | Fortgesetzt | B. Riley FBR | Buy |
2018-07-06 | Bestätigt | Chardan Capital Markets | Buy |
2018-04-10 | Hochstufung | B. Riley FBR, Inc. | Neutral → Buy |
2018-03-13 | Bestätigt | B. Riley FBR, Inc. | Neutral |
2018-02-23 | Herabstufung | B. Riley FBR, Inc. | Buy → Neutral |
2018-01-25 | Bestätigt | H.C. Wainwright | Buy |
2017-11-01 | Bestätigt | B. Riley FBR, Inc. | Buy |
Alle ansehen
Iovance Biotherapeutics Inc Aktie (IOVA) Neueste Nachrichten
Metastatic Melanoma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Evaxion Biotech, InxMed, AiVita Biomedical, Iovance Biotherapeutics, Viralyt - Barchart.com
Iovance stock gains as Replimune drug rejected (IOVA:NASDAQ) - Seeking Alpha
Metastatic Melanoma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis Evaxion Biotech, Inxmed, Aivita Biomedical, Iovance Biotherapeutics, Viralyt - MenaFN
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Fly 26% But Investors Aren't Buying For Growth - simplywall.st
Iovance Biotherapeutics Inc Inc. (IOVA) Price Performance: The Role of Share Buybacks and Stock Splits - investchronicle.com
Is Iovance Biotherapeutics Inc. a good long term investmentConsistently superior profits - jammulinksnews.com
This Healthcare Stock Just Hit a 52-Week Low -- but Wall Street Sees 380% Upside - Yahoo Finance
Iovance Biotherapeutics Inc. Stock Analysis and ForecastExplosive returns - printweek.in
Zacks Research Issues Pessimistic Estimate for IOVA Earnings - Defense World
What drives Iovance Biotherapeutics Inc. stock priceFree Risk Assessment Services - jammulinksnews.com
What analysts say about Iovance Biotherapeutics Inc. stockFree Stock Selection - jammulinksnews.com
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Iovance: I'm Switching From Sell To Buy Despite Likely Approval For Rival Drug - Seeking Alpha
Iovance Biotherapeutics (NASDAQ:IOVA) Cut to Sell at The Goldman Sachs Group - Defense World
Iovance Biotherapeutics’ SWOT analysis: TIL therapy stock faces challenges amid potential - Investing.com
Iovance BioTherapeutics Sees Positive Trends with New Appointments and Promising Cancer Study - StocksToTrade
Iovance Biotherapeutics Appoints New Chief Financial Officer - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Eli Lilly & Co (LLY) - The Globe and Mail
Barclays Reaffirms Their Buy Rating on Iovance Biotherapeutics (IOVA) - The Globe and Mail
IOVANCE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
IOVANCE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Iovance Biotherapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Iovance Biotherapeutics: Legal Woes Shake Investor Confidence - timothysykes.com
Iovance Biotherapeutics Faces Legal Hurdles Amid Investor Concerns - StocksToTrade
Iovance Biotherapeutics, Inc. Appoints Corleen Roche as Chief Financial Officer, Effective August 6, 2025 - MarketScreener
Why Iovance Biotherapeutics Inc. stock attracts strong analyst attentionMulti Bagger Alerts - Newser
Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer - GlobeNewswire
Sector Update: Health Care Stocks Mixed Premarket Tuesday - MarketScreener
Iovance Biotherapeutics Names Corleen Roche as Chief Financial Officer - MarketScreener
Citizens JMP reiterates Market Perform rating on Iovance stock By Investing.com - Investing.com Canada
Goldman Sachs downgrades Iovance Biotherapeutics stock to Sell on Amtagvi adoption challenges - Investing.com Canada
Cambridge Investment Research Advisors Inc. Acquires 5,237 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - Defense World
Amtagvi shows 61% response rate in less heavily treated melanoma patients - Investing.com Australia
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) Investor Alert: Deadline in Lawsuit on July 14, 2025 - openPR.com
Levi & Korsinsky Reminds Iovance Investors of the Pending - GlobeNewswire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics - The Globe and Mail
IOVA FINAL DEADLINE ALERT: Hagens Berman Alerts Iovance - GlobeNewswire
FINAL IOVANCE DEADLINE ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
The Iovance Biotherapeutics Lawsuit: A Cautionary Tale of Investor Protection and Timely Legal Action - AInvest
Lost Money on Iovance Biotherapeutics, Inc.(IOVA)? Join Class Action Suit Seeking RecoveryContact The Gross Law Firm - MarketScreener
Iovance Says Amtagvi Shows 49% Response Rate in Real-World Skin Cancer Study - MarketScreener
Iovance Biotherapeutics Reports 61% Response Rate for Amtagvi® in Third-Line Melanoma Patients - Nasdaq
New Real-World Data: Iovance's Melanoma Drug Amtagvi Achieves Breakthrough 61% Response Rate - Stock Titan
Lost Money on Iovance Biotherapeutics, Inc. (IOVA)? Join Class Action Before July 14, 2025Contact Levi & Korsinsky - ACCESS Newswire
IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - MarketScreener
July 14, 2025 Deadline: Join Class Action Lawsuit Against Iovance Biotherapeutics, Inc. (IOVA)Contact Levi & Korsinsky - ACCESS Newswire
Securities Lawsuit Alert: Iovance Biotherapeutics, Inc. (IOVA) InvestorsContact Levi & Korsinsky Before July 14, 2025 - ACCESS Newswire
IOVA Deadline: IOVA Investors with Losses in Excess of $100K Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit - The Malaysian Reserve
Finanzdaten der Iovance Biotherapeutics Inc-Aktie (IOVA)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):